Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: The Insulin Resistance Atherosclerosis Study (IRAS)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 562-568

  Festa, Andreas ^a,e   D'Agostino Jr , Ralph ^b   Mykkänen, Leena ^a   Tracy, Russell P ^c   Zaccaro, Daniel J ^b   Hales, C Nick ^d   Haffner, Steven M ^a  

^a Univ of Texas Health Science Center ^*  (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Fibrinogen; Insulin; Non insulin dependent diabetes mellitus; Plasminogen activator inhibitor 1; Proinsulin

Indexed keywords

FIBRINOGEN; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; FIBRINOLYSIS; GLUCOSE TOLERANCE; HEMOSTASIS; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0033050497     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.562     Document Type: Article

References (63)

1. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2 year follow-up of the Helsinki Policeman Study population. Acta Med Scand. 1985;701(suppl):38-52.
2. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study 10 years later. Horm Metab Res. 1985;15(suppl):41-46.
3. Després JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
4. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137:959-965.
5. Howard G, O'Leary DH, Zaccaro D, Haffner SM, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809-1817.
6. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990; 13:631-655.
7. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest. 1985;75:809-817.
8. Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, Bonati PA, Berganzani M, Gnudi L, Passeri M, Reaven G. Risk factors for coronary artery disease in healthy persons with hyperinsulinaemia and normal glucose tolerance. N Engl J Med. 1989;320:702-706.
9. Orchard TJ, Becker DJ, Bates M, Kuller LH, Drash AL. Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol. 1983;118:326-337.
10. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism. 1988;37:338-345.
11. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
12. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
13. Garg A, Gelderman JH, Koffler M, Ayuso R, Rosenstock J, Raskin P. Relationship between lipoprotein levels and in vivo insulin action in normal white men. Metabolism. 1988;37:982-987.
14. Abbott WGH, Lillioja S, Young AA, Zawadzki JK, Yki-Jarvinen H, Christin L, Howard BV. Relationship between plasma lipoprotein concentrations and insulin concentrations and insulin action in an obese hyperinsulinaemic population. Diabetes. 1987;36:897-904.
15. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
16. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stem MP. Prospective analyses of the insulin resistance syndrome (syndrome X). Diabetes. 1992;41:715-722.
17. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in NIDDM. Ann Med. 1996;28:371-380.
18. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
19. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672-676.
20. Ganda OP, Arkin CH. Hyperfibrinogenaemia: an important risk factor for vascular complications in diabetes. Diabetes Care. 1992;15:1245-1250.
21. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb. 1993;13:1865-1873.
22. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
23. Mohamed-Ali V, Gould MM, Gillies S, Goubet S, Yudkin JS, Haines AP. Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects: evidence against a modulating role for insulin. Diabetologia. 1995;38:1110-1116.
24. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
25. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945-949.
26. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo-and hypertriglyceridaemic men. Diabetologia. 1993;36:817-825.
27. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
28. Temple RC, Clark P, Schneider A, Nagi DK, Yudkin JS, Hales CN. Insulin deficiency in non-insulin dependent diabetes. Lancet. 1989;1: 293-295.
29. Gray RP, Panahloo A, Mohamed-Ali V, Patterson DLH, Yudkin JS. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis. 1997;130:171-178.
30. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for cardiovascular disease. Circulation. 1994;89: 321-330.
31. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin in vivo. Circulation. 1995;91: 764-770.
32. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PM, Schneider AE, Hales CN, Yudkin JS. The relationship of concentrations of insulin, intact proinsulin, and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1990;33:532-537.
33. Haffner SM, Mykkänen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in non-diabetic subjects. Diabetes. 1993;42:1297-1302.
34. Wagenknecht LE, Mayer EJ, Rewers M, Haffner SM, Selby J, Borok GM, Henkin L, Howard G, Savage PJ, Saad MF, Bergman RN, Hamman R. The Insulin Resistance Atherosclerosis Study (IRAS): objectives, design and recruitment results. Ann Epidemiol. 1995;5:464-471.
35. Stern MP, Rosenthal M, Haffner SM, Hazuda HP, Franco LJ. Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans: the San Antonio Heart Study. Am J Epidemiol. 1984;120:834-851.
36. Hamman RF, Marshall JA, Baxter J, Kahn LB, Mayer EJ, Orleans M, Murphy JR, Lezotte DC. Methods and prevalence of non-insulin dependent diabetes mellitus in a biethnic Colorado population: the San Luis Valley Diabetes Study. Am J Epidemiol. 1989;129:295-311.
37. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1985. Technical report series No 727.
38. Herbert V, Lau K, Gottlieb C, Bleicher S. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 1965;25:1375-1384.
39. Sobey WJ, Beer SF, Carrington CA, Clark PM, Frank BH, Gray IP, Luzio SD, Owens DR, Schneider AE, Siddle K, Temple RC, Hales CN. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulin. Biochem J. 1989;260: 535-541.
40. Ostrega D, Polonsky K, Nagi D, Yudkin J, Cox LJ, Clark PMS, Hales CN. Measurement of proinsulin and intermediates: validation of immunoassay methods by high-performance liquid chromatography. Diabetes. 1995;44:437-440.
41. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocrinol Rev. 1985;6:45-86.
42. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed. 1986;23:113-122.
43. Welch S, Gebhart SSP, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 1990;71:1508-1518.
44. Steil GM, Volund A, Kahn SE, Bergman RN. Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes. 1993; 42:250-256.
45. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YDI, Sands RE, Pei D, Savage PJ, Bergman RN. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes. 1994;43: 1114-1121.
46. Geffken D, Keating F, Kennedy M, Cornell E, Bovill E, Tracy R. The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med. 1994;118: 1106-1109.
47. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
48. Macy E, Meilahn E, Declerck P, Tracy R. Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies. Arch Pathol Lab Med. 1993;117:67-70.
49. Declerck P, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res. 1990;10(suppl):3-9.
50. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure: the Northern Sweden MONICAStudy. J Clin Epidemiol. 1994;47:513-524.
51. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
52. Gray RP, Vidya Mohamed-Ali V, Patterson DL, Yudkin JS. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost. 1995;73:261-267.
53. Båvenholm P, Proudler A, Silveira A, Crook D, Blombäck M, de Faire U, Hamsten A. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Thromb Haemost. 1995;73:568-575.
54. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988;60: 491-494.
55. Eliasson M, Røder ME, Dinesen B, Evrin PE, Lindahl B. Proinsulin, intact insulin, and fibrinolytic variables and fibrinogen in healthy subjects. Diabetes Care. 1997;8:1252-1255.
56. Nagi DK, Knowler WC, Hanson RL, Mohamed Ali V, Yudkin JS. Plasminogen activator inhibitor (PAI-1) and non-insulin-dependent diabetes in Pima Indians, South Asians and Europeans: populations at varying risk of NIDDM and coronary artery disease. Thromb Haemost. 1996;75:921-927.
57. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995;44:37-42.
58. Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes. 1992;41:890-895.
59. Missov RM, Stolk RP, van der Bom JG, Hofman A, Bots ML, Pols HA, Grobbee DE. Plasma fibrinogen in NIDDM: the Rotterdam study. Diabetes Care. 1996;19:157-159.
60. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R, Müller M. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:1045-1050.
61. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
62. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol. 1992;2:457-466.
63. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentration: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol. 1998;18:84-91.